Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect.

Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect.

Bhattarai Shreeyukta; Pupillo Stephen; Man Singh Dangol Gulshan; Sarac Erdal

Case reports in nephrology

2019

2019

Hyperkalemia, a potential life threating condition, is a commonly encountered problem in chronic kidney disease (CKD) patients. Patiromer acetate, a nonabsorbable cation exchange polymer, is a gastrointestinal agent for chronic therapy in patients with persistent hyperkalemia. Patiromer is generally well tolerated in patients; common side effects are gastrointestinal, such as diarrhea, constipation, flatulence, and vomiting. Hypercalcemia, although a theoretical possibility, has not been reported in any major clinical trials. We present a case of hypercalcemia associated with patiromer acetate used for treatment of hyperkalemia in a stage IV CKD patient. Clinicians should be aware of the possibility of hypercalcemia while taking patiromer.

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

3507407-3507407

2019